The story of CRISPR is a fascinating journey of scientific discovery and innovation.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) was first discovered in the late 1980s by Japanese scientist Yoshizumi Ishino while studying the DNA of E. coli bacteria. However, its significance wasn’t fully understood at that time.
Fast forward to the early 2000s, scientists noticed these strange repeating sequences in the genomes of various bacteria and archaea. It was Jennifer Doudna, a biochemist at the University of California, Berkeley, and her collaborator Emmanuelle Charpentier, who played a pivotal role in unlocking the potential of CRISPR.
Bacteria use CRISPR as a sort of immune system to defend themselves against viruses that infect them, known as bacteriophages. CRISPR is like a genetic memory that helps bacteria remember and fight off previous viral attacks.
Here’s how it works:
- Viral Infection: When a bacteriophage attacks a bacterium, it injects its genetic material into the bacterium’s cell. The bacterium recognizes the invader and tries to protect itself.
- DNA Capture: The bacterium’s CRISPR system captures a small piece of the viral DNA and stores it in its own genome as a “spacer.” This spacer becomes part of the bacterium’s genetic memory.
- Guide RNA Production: Later, if the same virus attacks again, the bacterium uses the CRISPR system to transcribe the stored spacer into a guide RNA molecule. This guide RNA carries the memory of the previous viral encounter.
- Cas Protein Activation: The guide RNA guides a protein called Cas (CRISPR-associated protein) to the matching spot on the viral DNA.
- DNA Cleavage: Once the Cas protein is at the right location, it acts as molecular scissors, cutting the viral DNA and disabling the virus’s ability to infect the bacterium.
By using CRISPR, bacteria are able to “remember” the viruses that attacked them in the past and quickly mount a defense against those same viruses if they return. It’s like having a genetic mugshot of the virus stored in their DNA, allowing them to neutralize the threat before it can harm them.
This natural defense mechanism of bacteria has been harnessed by scientists to create the powerful gene-editing tool known as CRISPR-Cas9, which allows precise modification of genes in a wide range of organisms, including plants, animals, and even humans.
In 2012, Doudna and Charpentier published a groundbreaking paper that explained how CRISPR could be turned into a powerful gene-editing tool. They described how a molecule called “guide RNA” could be programmed to target specific DNA sequences, guiding a protein called Cas9 to that precise location. Cas9 would then act like molecular scissors, cutting the DNA at that spot. This discovery sparked tremendous excitement within the scientific community.
The ability to precisely edit genes using CRISPR-Cas9 had a revolutionary impact on various fields, from medicine to agriculture. It opened the door to correcting genetic mutations that cause diseases, developing more resilient crops, and even engineering cells for research purposes.
However, the story of CRISPR also involves a legal and ethical dimension. A patent dispute ensued over who had the rights to the technology, involving Doudna’s team and another group led by Feng Zhang at the Broad Institute. Ultimately, both teams made significant contributions, and the patent was awarded to both sides.
As CRISPR’s potential became more apparent, discussions on its ethical use grew louder. Questions about “designer babies,” unintended consequences, and responsible use of gene editing technology emerged. Scientists, policymakers, and the public began grappling with the moral and societal implications of such a powerful tool.
Despite the challenges, the CRISPR story continues to evolve. Researchers are continually refining and expanding its capabilities, exploring new avenues in medicine, biotechnology, and beyond. CRISPR has empowered scientists to rewrite the code of life, offering a glimpse into a future where genetic diseases could be treated and new possibilities in genetics are unlocked.
Sharetreck - Tracking Genomic Investments & clinical trials for HIV. 